Replies to post #70320 on Biotech Values

[DewDiligence]

Re: FTY720

>Too late for the FREEDOMS trials to test for a lower dose but regardless, it would be very difficult to do a lower dose placebo-controlled study, especially in the U.S. as you've mentioned in the quiz.<

I should have pointed out that 1.25mg is the only dose being tested in the phase-3 trial in PPMS trial called INFORMS.

[DewDiligence]

NVS reports FTY720 data from the phase-3 FREEDOMS trial at the ECTRIMS conference tomorrow. Unlike the successful TRANFORMS trial (#msg-34138493, #msg-34138665), FREEDOMS includes 24 months of treatment, and hence (if successful) it meets the duration requirement for an agent to be considered disease modifying in MS.

I think a survey is in order.